Erosive Esophagitis
0 original drugsErosive Esophagitis has 0 FDA-approved novel treatments across 3 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Phase 3 Readouts Pro
1 active Phase 3 trial with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Erosive Esophagitis Treatments by Mechanism
Top 1 mechanisms across 4 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Erosive Esophagitis Clinical Pipeline by Phase
26 industry-sponsored trials across 12 sponsors
Novel Erosive Esophagitis Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (8 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Erosive Esophagitis Drug Targets
Molecular targets of approved and investigational Erosive Esophagitis drugs — 3 targets tracked.
Generic Drugs (6 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs